Close menu




March 8th, 2021 | 10:59 CET

AT&T, Altria Group, Q&M Dental - Dividend hunters, watch out!

  • Investments
Photo credits: pixabay.com

We live in uncertain times. And not just since Covid-19 came on the scene. Even before that, interest rates were at rock bottom thanks to the central banks' flood of money. Alternative return concepts were needed: cryptocurrencies, tokens, ICOs, etc. If all this is too hot for you, you might want to think about something that has always promised a sustainable return: the dividend. With dividend yields around 5% or above, the following stocks are attractive securities for every wallet from an investor's perspective.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: US00206R1023 , US02209S1033 , SG2E73981531

Table of contents:


    AT&T - Dividend aristocrat with an uninterrupted increase for 37 years

    US telecommunications giant AT&T has been paying an uninterruptedly increasing dividend for 37 years, making it one of a class of stocks known as the Dividend Aristocrats. The last annual dividend was USD 2.08, and the dividend yield was 7.24%. As is customary with US stocks, the dividend is paid quarterly. Most recently, there had been discussions about whether AT&T should possibly cut its dividend, which the Company was able to fully finance from its cash flow, in order to have more funds for a corporate restructuring - primarily due to its weakening business with its satellite TV subsidiary DirecTV.

    However, at the end of February, the Company announced that DirecTV would be transferred to a joint venture with TPG Capital, which should provide the Group with a cash inflow of USD 7.6 billion in the second half of the year. The crisis seems to have been averted here for the time being. Another construction site is the film studio WarnerMedia (formerly Time Warner), which was acquired in mid-2018 and is currently generating hardly any box office revenues due to the pandemic. The start of numerous productions has also had to be postponed.

    On March 12, the Company plans to provide further guidance at an analyst conference. Anyone interested in the title can get the latest information here on how the Group is to continue. We assume that the Company will not shake its dividend policy in the near future.

    Q&M Dental Group - No aristocrat, but a lot of potential

    How does a penny stock go together with dividends? Quite simply, some stocks cost only a few cents but still pay dividends. Q&M Dental Group from Singapore is one of those stocks. Founded in 1996, the Company is now Asia's largest private dental Group with 114 medical practices, 5 dental clinics and 3 sales companies. Q&M Dental is by far the leading private provider of dental services in Singapore. The share, which is also traded in Frankfurt, is currently trading at around SDG 0.60. Since the beginning of the year, the share price has already risen by around 30%.

    One of the reasons for this is the Company's dividend policy, which is boosting investor confidence in the stock. With the announcement of the last figures on March 1, the Company announced a profit increase of 10% to SGD 19.7 million and the payment of a regular dividend of 0.5 cents per share as well as a special dividend of 2.5 cents. As a result, the dividend yield is just under 5% p.a. In 2020, it did not initially look as if this would be a good year for companies in the dental sector. Even more than in other countries, dental services were suspended in Singapore due to the Covid-19 pandemic.

    However, the Company responded promptly and became involved in the distribution of Covid-19 test and laboratory kits. For the future, the Company is focusing on expanding its franchise system to include countries such as China and Malaysia, as well as the use of artificial intelligence (AI) in everyday practice. Also, the opening of 10 dental clinics, which could not occur in 2020 due to the pandemic, is now to be made up for in 2021. Therefore, the prospects are excellent for investors who want to benefit from the current dental boom in Asia and the strong demand for Covid-19 test and laboratory kits.

    Altria Group - Uninterrupted dividend growth for 51 years

    Another Dividend Aristocrat is the US-based Altria Group, better known as the corporate parent of Philip Morris and one of the largest cigarette producers in the world. Following the sale of its 87% stake in Kraft Foods in 2008, Ste. Michelle Wine Estates is the only operating unit left in the conglomerate that is not involved in tobacco products. However, the Group still holds significant stakes in other companies, such as AB InBev (around 10%), Canadian cannabis producer Cronos Group (about 45%) and e-cigarette brand JUUL Labs (about 35%).

    On February 26, the Company announced a quarterly dividend of USD 0.86, equivalent to USD 3.44 for the year. The dividend yield was thus 7.89% on the record date. The ex-dividend date is March 24. In the course of the presentation of the quarterly figures, the Group outlined its vision of how, in the face of increasing global regulation, it could detach itself from its main business of combustion tobacco and turn to new business areas.

    22% of sales are currently already made with tobacco alternatives consumed "without combustion" (tobacco sticks, pouches). The extent to which this can allay moral concerns about an investment in a cigarette company is a matter for each investor to decide for himself. In any case, the share price has performed well since the beginning of the year, rising by 12%. And from a dividend point of view, the Company also seems to be a safe bank. For the time being, anyway.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read